Results 181 to 190 of about 193,702 (280)

Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial. [PDF]

Future Oncol
Ahn MJ, Delmonte A, Ghosh S, Hochmair M, Yang TY, Yang JC, Han JY, Hansen KH, Wu Y, Wan Y, Lin HM, Kretz J, Hupf B, Kurec AM, Churchill EN, Fram RJ, Cabasag CJ, Goriya V, Zhao Y, Campelo MRG.   +19 more
europepmc   +1 more source

Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer [PDF]

, 2017
et al,, Govindan, Ramaswamy
core   +1 more source

Development of Betalactam‐Predictor: A Clinical Decision Tool for Delabeling Low‐Risk Betalactam Allergy Patients. Initial Validation in Penicillin Allergy

Allergy, EarlyView.
BL‐Predictor has emerged as a new tool for delabeling penicillin allergy. External validation has shown a specificity of 93% for detecting low‐risk patients. This score could potentially reduce diagnostic costs and the negative consequences associated with incorrect antibiotic allergy labels.
Marina Labella, Rafael Nuñez, Inmaculada Doña, Julia Rodríguez de Guzmán, Esther Moreno, Lene Heise Garvey, Jose Julio Laguna, Annick Barbaud, Patrizia Bonnadona, Jonas Bredtoft Boel, Holger Mosbech, Giovanna Sfriso, Mariana Castells, Elizabeth Phillips, María José Torres   +14 more
wiley   +1 more source

EML4-ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis. [PDF]

Cancer Discov
Diaz-Jimenez A, Shuldiner EG, Somogyi K, Shih KY, González-Velasco Ó, Najajreh M, Kim S, Akkas F, Murray CW, Andrejka L, Tsai MK, Brors B, Hofmann I, Sivakumar S, Sisoudiya SD, Sokol ES, Cai H, Petrov DA, Winslow MM, Sotillo R.   +19 more
europepmc   +1 more source

Early Risk Assessment and Recognition of Allergies in Children: Rationale, Methodology, and Proposed Algorithms

Allergy, EarlyView.
ABSTRACT Background Atopic diseases—including atopic dermatitis (AD), food allergy (FA), allergic rhinitis (AR), and asthma—are the most common chronic conditions in childhood and adolescence, affecting up to 30% of the global population. In Germany alone, more than 2.1 million children and adolescents are affected.
E. Hamelmann, B. Schaub, K. Beyer, K. Blümchen, M. Gerstlauer, M. V. Kopp, L. Lange, S. Lau, N. Maison, H. Ott, S. M. Schmidt, T. Spindler, C. Traidl‐Hoffmann, C. Vogelberg   +13 more
wiley   +1 more source

Ivonescimab combined with chemotherapy shows promising efficacy in an ALK fusion-positive lung adenocarcinoma patient with ALK-TKI resistance: a case report. [PDF]

Front Oncol
Lin M, Gao Y, Deng J.
europepmc   +1 more source

Decreased PTGES2 Farnesylation in Granulosa Cells Compromises PGE2-Dependent Cumulus Expansion and Oocyte Maturation During Ovarian Aging. [PDF]

Aging Cell
Zhang S, Qi J, Liu C, Zhang H, Guo B, Wu D, Liu Y, Zhen X, Zhang Y, Kang N, Zhou J, Yan G, Li C, Ding L, Sun H.   +14 more
europepmc   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

A cost-effectiveness analysis model of actionable genomic alteration testing strategies incorporating different modalities and sizes of next-generation sequencing panels in non-small-cell lung cancer. [PDF]

Ther Adv Med Oncol
Ang YLE, Ong JCM, Huang Y, Low JL, Sooi K, Nützinger J, Wang XJ, Gibbs M, Goh BC, Soo RA.   +9 more
europepmc   +1 more source

Comorbid Chronic Rhinosinusitis and Asthma: Shared Risk Factors and Treatment Implications—An EAACI Task Force Report

Allergy, EarlyView.
ABSTRACT Chronic rhinosinusitis (CRS) and asthma are prevalent conditions that often coexist. These diseases share common inflammatory mechanisms, such as T‐helper cell 2 (T2)‐high inflammation, driven by interleukin (IL)‐4, IL‐5, and IL‐13 cytokines.
Sanna Toppila‐Salmi, Sietze Reitsma, Valérie Hox, Simon Gane, Philippe Gevaert, Juan Maza‐Solano, Alma Helevä, Ida Sulku, Kaisa Santala, Iiris Kangasniemi, Ludger Klimek, Adam Chaker, Aspasia Karavelia, Michael Rudenko, Oliver Pfaar, Laura Van Gerven, Shaari Ariana, Michele Schiappoli, Marie Lundberg, Jan Hagemann, Ibon Eguíluz‐Gracia, Andre Moreira   +21 more
wiley   +1 more source